UBS raised the firm’s price target on Johnson & Johnson to $214 from $190 and keeps a Buy rating on the shares.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JNJ:
- Morning Movers: Albertsons gains, Goldman falls after quarterly results
- JNJ Earnings: Johnson & Johnson Stock Falls Despite Guidance Boost and Orthopedics Spin-Off Plans
- Johnson & Johnson Reports Strong Q3 2025 Financial Results
- Options Volatility and Implied Earnings Moves Today, October 14, 2025
- Johnson & Johnson declares Q4 dividend of $1.30 per share